T3 50mcg/tab 100 Tabletten by Genesis

Usage

1. Establish your target peak dose before starting: decide whether you are aiming for 75 mcg or 100 mcg daily at the pyramid apex, as this determines the number of escalation steps required and the total cycle length.
2. Take the first dose of 25 mcg (half a tablet) in the morning with water, at least 30 minutes before food, to maximise absorption consistency across all dose levels.
3. Advance by one increment (12.5–25 mcg) only after completing a full five-to-seven-day period at the current dose without exceeding your pre-set cardiovascular tolerance thresholds (resting heart rate below 90 bpm, no persistent temperature above baseline).
4. At the pyramid apex, maintain the peak dose for no more than two weeks before initiating the taper — extended peak-dose exposure increases suppression depth and lengthens the recovery window after cessation.
5. Taper using the exact reverse sequence of your escalation: if you added dose in three steps up, remove dose in three equivalent steps down, spending five to seven days at each step.
6. After the final 25 mcg taper day, discontinue completely and allow a minimum of four weeks before considering another T3 cycle; use this window to assess thyroid axis recovery through symptom monitoring and, ideally, fT3/TSH laboratory testing.

Warnings

Frequently asked questions

How do you build up the dose of Genesis T3 step by step using a pyramid approach?

Start at 25 mcg daily (half a tablet) for five to seven days, then add 12.5–25 mcg per increment every five to seven days until reaching your planned peak. Most users reach 75–100 mcg per day at the pyramid's apex. Because Genesis T3 tablets contain a consistent 50 mcg of HPLC-verified Liothyronine, each half- or full-tablet step delivers a pharmacologically predictable dose adjustment.

Why is a slow taper off T3 important and what happens if you stop abruptly?

A slow taper is essential because exogenous T3 suppresses endogenous thyroid output during use, and abrupt cessation removes the thermogenic stimulus before natural production can recover. Reducing by 12.5–25 mcg every five to seven days mirrors the escalation rate and gives the hypothalamic-pituitary-thyroid axis time to resume baseline signalling — limiting the fatigue, cold sensitivity, and rapid fat regain that can follow an unplanned stop.

How do you know when you have reached the maximum appropriate daily dose during a T3 pyramid cycle?

Your maximum appropriate dose is signalled by a combination of objective markers — persistent resting heart rate above 90 bpm, night sweats, or significant sleep disruption — and subjective ones such as notable anxiety or pronounced muscle fatigue. Most experienced users cap total daily Liothyronine at 100 mcg; if any tolerance signals appear before that level, the previous increment becomes the effective ceiling for that cycle.

Can Genesis T3 50mcg tablets be split for the lower doses required during the early escalation phase?

Yes. The tablet's physical form allows mechanical splitting into approximate halves, yielding roughly 25 mcg per half-tablet — the standard entry dose for a pyramid protocol. While a scored tablet design would maximise splitting accuracy, consistent HPLC-verified content uniformity across the Genesis T3 batch means that even mechanically split halves remain within a clinically acceptable potency range for the initiation phase.

How are Genesis T3 tablets packaged and does the packaging support accurate counting during a multi-week titration cycle?

Genesis T3 comes in a 100-tablet unit, which conveniently covers a full pyramid-and-taper cycle of six to eight weeks without requiring multiple orders mid-cycle. The discrete bottle or blister packaging keeps tablets protected from humidity and light, preserving potency across the duration of the cycle — important when early low-dose tablets from the same batch will be taken weeks after the package is first opened. (2) angle_used

Manufacturer

Genesis brings the same multi-stage quality architecture used across its broader oral tablet portfolio to the Liothyronine 50 mcg line — adapted specifically for the precision demands of a compound where a single 25 mcg step separates a therapeutically appropriate dose from one that drives adverse cardiovascular load. The Liothyronine sodium API undergoes incoming qualification through HPLC quantification referenced against a certified primary standard, establishing the raw-material potency record before any manufacturing step begins. Tablet compression and blending occur within ISO-classified, humidity-controlled suites monitored by continuous in-process environmental controls; finished tablets are then drawn by stratified sampling from each batch and re-assayed by HPLC to confirm that declared per-tablet content of 50 mcg falls within validated acceptance limits. Endotoxin burden in the API stream is assessed by LAL methodology prior to release. These sequential, independently documented quality gates — incoming API qualification, in-process environmental monitoring, and finished-product HPLC release — collectively ensure that the content uniformity required for a pharmacologically predictable pyramid-and-taper protocol is present in every tablet the end user receives.